The Metabolic Effects of Drugs Used for the Treatment of Polycystic Ovary Syndrome

September 2013 in “ Journal of the Turkish-German Gynecological Association ”

Melia Karaköse, Erman Çakal, Kubilay Ertan, Tuncay Delibaşı

polycystic ovary syndrome PCOS hyperandrogenism endocrine disorder carbohydrate metabolism cardiovascular disease lipid profiles

Studysummary This review discusses the impact of various drugs on metabolic parameters in women with polycystic ovary syndrome, without reporting new clinical findings.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The review discussed the metabolic effects of various drugs used to treat polycystic ovary syndrome (PCOS), a common endocrine disorder in women of reproductive age characterized by menstrual disorders, hyperandrogenism, and specific ultrasonographic features. PCOS negatively impacted carbohydrate metabolism, cardiovascular disease parameters, and lipid profiles. The treatment approach was tailored to the patient's primary complaint, and numerous medications had been employed over the years. The review aimed to assess how these drugs influenced the metabolic risk profile in women with PCOS.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline

1265 citations , October 2013 in “The Journal of Clinical Endocrinology and Metabolism”

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

research The Androgen Excess and PCOS Society Criteria for the Polycystic Ovary Syndrome: The Complete Task Force Report

1540 citations , October 2008 in “Fertility and Sterility”

This review discusses the definition of polycystic ovary syndrome proposed by the AE-PCOS Society Task Force, emphasizing hyperandrogenism, ovarian dysfunction, and excluding related disorders, while noting potential variations needing more research.

research Sexual Hormones in Human Skin

305 citations , February 2007 in “Hormone and metabolic research”

This review discusses the roles of androgens and estrogens in skin functions and disorders, and highlights the use of estrogen-progestin treatments and anti-androgens in managing hirsutism and acne, without reporting new results.

research Recent Advances in the Treatment of Polycystic Ovary Syndrome

12 citations , October 2004 in “Expert Opinion on Investigational Drugs”

This review discusses current and emerging therapeutic strategies for managing polycystic ovary syndrome, emphasizing treatment tailored to individual patient complaints and highlighting the roles of hormone therapy and insulin-sensitizing agents.

research Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome

4809 citations , January 2004 in “Fertility and Sterility”

This review discusses polycystic ovary syndrome, emphasizing its broad range of manifestations and associations with risks like type 2 diabetes and cardiovascular events, but reports no new clinical results.

research Polycystic Ovary Syndrome and Cardiovascular Disease: A Premature Association?

418 citations , June 2003 in “Endocrine Reviews”

This review discusses the relationship between polycystic ovary syndrome and cardiovascular risk, noting a possible adverse impact on risk profiles and subclinical atherosclerosis but no clear increase in premenopausal cardiovascular events; it presents no new clinical results.

research Polycystic Ovary Syndrome and Insulin-Resistant Hyperinsulinemia

60 citations , September 2001 in “Journal of the American Academy of Dermatology”

This review discusses the relationship between insulin regulation and hyperandrogenemia in polycystic ovary syndrome, suggesting potential benefits of insulin-lowering treatments for ovarian function but reporting no definitive results for hair-related symptoms.

research Prevalence of Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study

378 citations , September 1998 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that the prevalence of PCOS in a population of unselected U.S. women was 4.0%, with no significant racial differences between White and Black women.

research Prevalence of Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study

633 citations , September 1998 in “The Journal of Clinical Endocrinology and Metabolism”

This study observed that among a cohort of reproductive-aged women in the U.S., the prevalence of PCOS was about 4.0%, with no significant racial differences between White and Black women.

research Comparison of Flutamide and Spironolactone in the Treatment of Hirsutism: A Randomized Controlled Trial

165 citations , February 1994 in “Fertility and Sterility”

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

research Androgen Metabolism in Hirsute Patients Treated with Cyproterone Acetate

64 citations , March 1984 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry”

In this study, cyproterone acetate combined with estradiol dramatically improved hirsutism symptoms and significantly reduced plasma testosterone and androstenedione levels in patients over periods of up to three years.